Patient/Caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE)-Reference-Cited by-同舟云学术

Patient/Caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE)

Published:2011-12-16 Issue:3 Volume:18 Page:392-399
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:

Author:

YOUNG G.,SHAPIRO A. D.,WALSH C. E.,GRUPPO R. A.,GUT R. Z.,COOPER D. L.

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2516.2011.02704.x/fullpdf

Reference17 articles.

1. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference;Berntorp;Haemophilia,2006

2. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99;Darby;J Thromb Haemost,2004

3. CDC (Centers for Disease Control and Prevention) Hemophilia facts http://www.cdc.gov/ncbddd/hemophilia/facts.html

4. Mechanism of action of factor VIIa in the treatment of coagulopathies;Hedner;Semin Thromb Hemost,2006

5. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors;Key;Thromb Haemost,1998

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors;Expert Review of Hematology;2023-09-25

2. Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements;Journal of Managed Care & Specialty Pharmacy;2022-05

3. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors;Haemophilia;2022-04-27

4. The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors;Haemophilia;2019-09-05

5. Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors;Haemophilia;2017-10-05